Mammalian target of rapamycin as a therapeutic target in oncology - PubMed (original) (raw)
Review
Mammalian target of rapamycin as a therapeutic target in oncology
Robert T Abraham et al. Expert Opin Ther Targets. 2008 Feb.
Abstract
Background: The mammalian target of rapamycin (mTOR) has emerged as a validated therapeutic target in cancer and mTOR inhibitors alter tumor cell responses to mitogenic signals and microenvironmental stress.
Objectives: The aims of this review are to describe the mTOR signaling pathway and the rationale for the use of rapamycin analogs and other mTOR inhibitors for oncology indications.
Methods: This review presents information from recent publications, as well as some more conjectural viewpoints stemming from the early clinical experience with mTOR inhibitors in cancer patients.
Results/conclusions: A thorough understanding of the antitumor mechanisms of the existing mTOR inhibitors will drive the development of effective combination therapies to overcome tumor resistance to these agents. Furthermore, the development of second-generation inhibitors of this critical protein target may yield deeper and broader therapeutic activities in human cancers.
Similar articles
- Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD, Buckner JC, Sarkaria JN. Rao RD, et al. Curr Cancer Drug Targets. 2004 Dec;4(8):621-35. doi: 10.2174/1568009043332718. Curr Cancer Drug Targets. 2004. PMID: 15578919 Review. - mTOR and cancer: insights into a complex relationship.
Sabatini DM. Sabatini DM. Nat Rev Cancer. 2006 Sep;6(9):729-34. doi: 10.1038/nrc1974. Epub 2006 Aug 17. Nat Rev Cancer. 2006. PMID: 16915295 Review. - Targeting mTOR for cancer treatment.
Rubio-Viqueira B, Hidalgo M. Rubio-Viqueira B, et al. Adv Exp Med Biol. 2006;587:309-27. doi: 10.1007/978-1-4020-5133-3_24. Adv Exp Med Biol. 2006. PMID: 17163174 Review. - New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. Albert S, et al. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review. - mTOR pathway and mTOR inhibitors as agents for cancer therapy.
Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. Baldo P, et al. Curr Cancer Drug Targets. 2008 Dec;8(8):647-65. doi: 10.2174/156800908786733513. Curr Cancer Drug Targets. 2008. PMID: 19075588 Review.
Cited by
- Natural products as chemical probes.
Carlson EE. Carlson EE. ACS Chem Biol. 2010 Jul 16;5(7):639-53. doi: 10.1021/cb100105c. ACS Chem Biol. 2010. PMID: 20509672 Free PMC article. Review. - Antineoplastic effects of mammalian target of rapamycine inhibitors.
Salvadori M. Salvadori M. World J Transplant. 2012 Oct 24;2(5):74-83. doi: 10.5500/wjt.v2.i5.74. World J Transplant. 2012. PMID: 24175199 Free PMC article. Review. - Inducing autophagy: a comparative phosphoproteomic study of the cellular response to ammonia and rapamycin.
Harder LM, Bunkenborg J, Andersen JS. Harder LM, et al. Autophagy. 2014 Feb;10(2):339-55. doi: 10.4161/auto.26863. Epub 2013 Nov 26. Autophagy. 2014. PMID: 24300666 Free PMC article. - The expanding universe of hypoxia.
Zhang H, Semenza GL. Zhang H, et al. J Mol Med (Berl). 2008 Jul;86(7):739-46. doi: 10.1007/s00109-008-0364-9. Epub 2008 Jun 13. J Mol Med (Berl). 2008. PMID: 18551266 Free PMC article. - Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
Ihle NT, Powis G. Ihle NT, et al. Mol Cancer Ther. 2009 Jan;8(1):1-9. doi: 10.1158/1535-7163.MCT-08-0801. Mol Cancer Ther. 2009. PMID: 19139107 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous